Who we are

SkylineDx is a high-tech, commercial-stage biotech company headquartered in Rotterdam, the Netherlands and a CAP/CLIA certified laboratory in San Diego, California, USA. The company uses its expertise to bridge the gap between academically discovered gene expression signatures and commercially available diagnostic products with high clinical utility. This process starts with synergistic collaborations with outstanding scientists. Step by step we prepare their discoveries for the market through further analysis and clinical validation. Thus, patients worldwide will benefit from ground-breaking scientific discoveries in diagnostics sooner and safer. It is in this exciting uncharted territory where we can truly make a difference.

Our role in DIAMONDS

SkylineDx will participate in the definition of criteria for platform comparison, the comparison of the candidate platforms, and the selection of a suitable platform for the subsequent clinical pilot study. We will be responsible for the technical assessment of the device performance, as well as the simulated clinical impact study where we’ll evaluate potential differences in clinical decisions based on the PMSD approach. In addition, SkylineDx will support the market landscaping and assess the viability of the PMSD approach and will also be responsible for the development of a business plan and a market strategy for commercialisation. Finally, we will support activities related to communication and stakeholder engagement and provide expertise on intellectual property management and technology transfer for the exploitation plan.

Our team

Dennie Tempel PhD is the Study Director at SkylineDx, where he designs and oversees all clinical and analytical studies in the various product development activities. He has extensive knowledge in the molecular diagnostic field and brings more than ten years of experience in translational and clinical research.

Danielle van Keulen PhD is a Scientist at SkylineDx, where she has been involved in the evaluation of novel diagnostic technologies, and is currently the scientific lead of development projects within SkylineDx.

Anton Ameneiro-Alvarez MSc supported the Business Development department at SkylineDx in identifying and evaluating new opportunities, and more recently, as Project Manager, coordinates new development projects within the organization, as well as third-party collaborations.

See all Partners
EU Flag

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 848196